Genomic Characterization of Duke Melanoma Brain Metastases

Request Access

Demographics (2)

Disease Events (15)

  • BODY_SITE - Body site where sample was collected (phv00526068.v1.p1)
  • BRAIN_METASTASES_PRESENT_AT_FIRST_DIAGNOSIS_OF_METASTATIC_DISEASE - Brain metastases present at first diagnosis of metastatic disease (phv00565022.v1.p1)
  • CLINICAL_MOLECULAR_TESTING - Clinical molecular testing (phv00565023.v1.p1)
  • HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00526071.v1.p1)
  • IS_TUMOR - Tumor status (phv00526070.v1.p1)
  • LOCATION_OF_PRIMARY_MELANOMA - Location of primary melanoma (phv00565020.v1.p1)
  • MELANOMA_TYPE - Melanoma type (phv00565019.v1.p1)
  • MONTHS_CRANIOTOMY_TO_LAST_FOLLOWUP - Months from craniotomy to death or last follow-up (phv00565030.v1.p1)
  • RADIATION_THERAPY - Radiation therapy (phv00565027.v1.p1)
  • RESULTING_MOLECULAR_CHARACTERISTICS - Resulting molecular characteristics (phv00565024.v1.p1)
  • STAGE_AT_DIAGNOSIS_OF_PRIMARY_MELANOMA - Stage at diagnosis of primary melanoma (phv00565021.v1.p1)
  • STATUS - Patient status at the time of last follow up (phv00565029.v1.p1)
  • TISSUE_TYPE - Tissue type, e.g. metastasis vs blood vs unspecified tumor (unknown if primary or metastasis) (phv00526072.v1.p1)
  • TRT_AFTER_CRANIOTOMY_SYSTEMIC - Systemic therapy treatment after craniotomy (phv00565026.v1.p1)
  • TRT_BEFORE_CRANIOTOMY_SYSTEMIC - Systemic therapy treatment before craniotomy (phv00565025.v1.p1)

Race and Ethnicity (1)

Other (14)